Last reviewed · How we verify
NCT03590886
Gut Microbes and Metabolic Group in Different PBC Patients for UDCA Response
trial testing total response Group in Primary Biliary Cirrhosis in 60 participants. Completed in 28 February 2019.
31 December 2018
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 22 August 2018 |
| Primary completion | 31 December 2018 |
| Estimated completion | 28 February 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- total response Group
Conditions studied
- Primary Biliary Cirrhosis — all drugs for Primary Biliary Cirrhosis →
Sponsor
Sun Yat-sen University
Who can join
Adults 30 to 70, any sex, with Primary Biliary Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To compare intestinal flora diversity in different PBC patients with UDCA responses, and further study the differences of bile acid metabolism and short chain fatty acid metabolism in feces and serum of two groups of PBC patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Emerging therapies for PBC.
Chascsa DMH, Lindor KD. · · 2020 · cited 16× · PMID 31970467 · DOI 10.1007/s00535-020-01664-0
Verify or expand the search:
- PubMed search for NCT03590886
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Biliary Cirrhosis
Currently open trials in the same condition.
- NCT06519162 — Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome · recruiting
- NCT04526665 — Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) · Phase 3 · active not recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03590886 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 24 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03590886.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing